English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Neuroendocrine neoplasms express somatostatinreceptors, enabling the use of somatostatin analogs formolecular imaging, when labeled with the positron-emitter 68Gafor receptor positron emission tomography/computedtomography (PET/CT), and targeted radionuclide therapy, whenlabeled with beta-emitters, e.g. 90Y and 177Lu.Aim: To investigate if 68Ga-DOTATATE PET-derivedstandardized uptake values (SUV) correlate with the dosedelivered to the liver lesions following 177Lu-DOTATATEradionuclide therapy in patients with neuroendocrine neoplasms.Materials and methods: Twelve adult (8M: 4F; mean age:55.9 ± 14.5 years; range: 23-78 years) patients with documentedneuroendocrine tumor (NET) disease and liver metastaseswere enrolled in the study. Ten patients were subjected to68Ga-DOTATATE and one patient each underwent 68Ga-DOTATOCand 68Ga-DOTANOC diagnostic PET/CT imaging.Subsequently, on the basis of positive PET/CT scan findingsfor the metastatic NET disease, all these patients were subjectedto peptide receptor radionuclide therapy (PRRNT) with 177Lu-DOTATATE. The reconstructed PET/CT data was used tocalculate the SUVs on the identifiable liver lesions. Thescintigraphic data acquired (anterior and posterior whole bodyimages) following therapeutic doses of 177Lu-DOTATATE weresubjected to the quantitative analysis (HERMES workstationand OLINDA/EXM software) to calculate the dose delivered tothe hepatic lesions.Results: The initial results of this preliminary study indicate poorcorrelation between SUV and the tumor dose and the linearregression analysis provided R2 values which explained only asmall fraction of the total variance.Conclusion: The SUVs derived from 68Ga-DOTA-peptide PET/CT images should be used with caution for the prediction oftumor dose on 177Lu-DOTA-peptide therapy as there are largeintra- and interpatient variability. Further studies with largenumbers of patients are warranted to establish such a correlationbetween SUV, tumor dose and the response assessment.

journal of postgraduate medicine, education and research

Can the Standardized Uptake Values derived from Diagnostic 68Ga-DOTATATE PET/CT Imaging Predict the Radiation Dose delivered to the Metastatic Liver NET Lesions on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy?